Efficacy of topical ropivacaine in children and young adults with hereditary epidermolysis bullosa

Moreno‐Artero, Ester; Schinkel, N; Chaumon, S.; Corset, I; Rabeony, Tioka; Elie, Caroline; Bellon, N.; Bodemer, Christine; Greco, Céline

doi:10.1111/bjd.19551

Cited by 4 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…• A recent study based on topical applications of a nondiluted injection formula of ropivacaine 0.2% on EB wounds during dressing changes showed that topical ropivacaine could reduce pain. 44 Nevertheless, there are some limitations of this pilot study due to the small number of patients and the short follow-up period. Particularly, long-term safety, tolerance and pharmacokinetics studies need to be performed before proposing routine clinical use.…”

Section: Agementioning

confidence: 94%

Practical management of epidermolysis bullosa: consensus clinical position statement from the European Reference Network for Rare Skin Diseases

Has

Hachem

Bučková

et al. 2021

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

Inherited epidermolysis bullosa (EB) comprises rare disorders that manifest with fragility and blistering of the skin and mucous membranes, with variable clinical severity. Management of EB is challenging due to disease rarity and complexity, the wide range of extracutaneous manifestations and a profound impact on daily life for the patient and family members. Although reference centres providing multidisciplinary care for EB exist in each European country, it is common for healthcare professionals that are not specialized in this rare disorder to treat EB patients. Here, experts of the European Reference Network for Rare and Undiagnosed Skin Diseases (ERN‐Skin, https://ern-skin.eu) propose practical recommendations for the diagnosis and management of the commonest clinical issues, skin blisters and wounds, oral manifestations, pain and itch.

show abstract

Section: Agementioning

confidence: 94%

Practical management of epidermolysis bullosa: consensus clinical position statement from the European Reference Network for Rare Skin Diseases

Has

Hachem

Bučková

et al. 2021

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several agents are in early phase trials but recommendations for best clinical practice are few. To reduce dressing change pain, application of 0.2% topical ropivacaine (anesthetic) 15 minutes before soaking the dressings was shown to reduce around 3 points of pain scale in 8 out of 10 patients without adverse effects [152].…”

Section: Analgesicsmentioning

confidence: 99%

Investigational Treatments for Epidermolysis Bullosa

et al. 2021

View full text Add to dashboard Cite

Epidermolysis bullosa (EB) is a heterogeneous group of rare inherited blistering skin disorders characterized by skin fragility following minor trauma, usually present since birth. EB can be categorized into four classical subtypes, EB simplex, junctional EB, dystrophic EB and Kindler EB, distinguished on clinical features, plane of blister formation in the skin, and molecular pathology. Treatment for EB is mostly supportive, focusing on wound care and patient symptoms such as itch or pain. However, therapeutic advances have also been made in targeting the primary genetic abnormalities as well as the secondary inflammatory footprint of EB. Pre-clinical or clinical testing of gene therapies (gene replacement, gene editing, RNA-based therapy, natural gene therapy), cell-based therapies (fibroblasts, bone marrow transplantation, mesenchymal stromal cells, induced pluripotential stem cells), recombinant protein therapies, and small molecule and drug repurposing approaches, have generated new hope for better patient care. In this article, we review advances in translational research that are impacting on the quality of life for people living with different forms of EB and which offer hope for improved clinical management.

show abstract

Management of pain in the inpatient and non-surgical outpatient dermatology settings: A narrative review

Bishnoi,

Shah,

Jain

et al. 2024

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

Pain is frequently encountered in dermatology practice, which impairs the activities of daily living, adds to psychological morbidity, and therefore compromises the quality of life. It ranges from mild to severe in intensity across various dermatoses and requires prompt addressal and treatment. Diseases such as extensive pemphigus vulgaris and Stevens–Johnson syndrome are especially painful and require a multidisciplinary approach with the involvement of a pain specialist in their management. The main pathogenic types of pain include visceral nociceptive, somatic nociceptive, and neuropathic types, the latter two being most relevant in dermatological disorders. Somatic nociceptive pain is often seen in patients of Stevens–Johnson syndrome/ Toxic epidermal necrolysis, epidermolysis bullosa, pemphigus vulgaris, erythema nodosum, and hidradenitis suppurativa, while neuropathic pain is part of the disease process in dermatoses like leprosy, herpes zoster, and dysesthesia syndromes. Therapeutic approaches to pain management include the use of non-opioids (acetaminophen, non-steroidal anti-inflammatory agents), opioids, and non-pharmacological therapies, along with appropriate management of the underlying dermatosis. World Health Organisation (WHO) analgesic ladder remains the most commonly employed guideline for the management of pain, although treatment needs individualisation depending on the nature and severity of pain (acute/chronic), type of dermatosis, and patient factors. There is a paucity of literature pertaining to pain management in dermatology and this topic is often neglected due to a lack of awareness and knowledge of the topic. The present review aims to discuss the pain pathway, various painful conditions in the setting of medical dermatology practice, and their management along with relevant pharmacology of the commonly used analgesics.

show abstract

Efficacy of topical ropivacaine in children and young adults with hereditary epidermolysis bullosa

Cited by 4 publications

References 8 publications

Practical management of epidermolysis bullosa: consensus clinical position statement from the European Reference Network for Rare Skin Diseases

Practical management of epidermolysis bullosa: consensus clinical position statement from the European Reference Network for Rare Skin Diseases

Investigational Treatments for Epidermolysis Bullosa

Management of pain in the inpatient and non-surgical outpatient dermatology settings: A narrative review

Contact Info

Product

Resources

About